Serrano C, et al. - Researchers examined patients with metastatic gastrointestinal stromal tumor (GIST) treated with continuous daily dosing of frontline imatinib, to study clinical, pathological, and molecular characteristics and long-term outcomes in a cohort of patients benefiting for ≥5 years vs in control group obtained from the national Spanish Group for Sarcoma Research database. They found that 34% complete responses and a median progression-free survival of 11 years were achieved by long-term responders (LTRs), whereas the control cohort achieved 4% complete responses and a median progression-free survival of 2 years. Overall, less aggressive behavior of GISTs and marked sensitivity to KIT inhibition was observed in LTRs. The likelihood of remaining progression free over time was noted to be higher among patients reaching 5 or more years on imatinib.